8-K: Curis Inc. Announces First Quarter 2024 Financial Results and Provides Business Update

Curis, Inc. reported its first quarter 2024 financial results, including a net loss of $11.9 million, and provided an update on its clinical programs, including upcoming data presentations at major oncology conferences.

Summary

• Curis, Inc. announced its financial results for the first quarter of 2024, reporting a net loss of $11.9 million, or $2.05 per share, compared to a net loss of $11.6 million, or $2.39 per share, for the same period in 2023.
• The company's revenue for the quarter was $2.1 million, slightly down from $2.3 million in the first quarter of 2023, primarily from royalties on Erivedge sales.
• Research and development expenses increased to $9.6 million, up from $9.1 million in the same quarter last year, mainly due to higher employee-related costs.
• General and administrative expenses were $4.9 million, compared to $4.8 million in the first quarter of 2023.
• Curis's cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024, and the company expects this to fund operations into 2025.
• The company plans to release topline clinical data from the TakeAim Leukemia study on May 14, 2024, and present additional data at the ASCO and EHA conferences.
• The clinical update will include data for 25 new patients, bringing the total to 30 targeted patients with R/R AML treated with emavusertib as a monotherapy.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is progressing with clinical trials and has a cash runway into 2025, the increased net loss and the need for additional capital raise concerns.

Positives

• Curis has a cash runway expected to last into 2025.
• The company is presenting updated clinical data at major oncology conferences.
• There is an increase in other income, net, due to a decrease in non-cash expense related to the sale of future royalties.

Negatives

• Curis reported a net loss of $11.9 million for the first quarter of 2024.
• Revenues decreased slightly to $2.1 million compared to $2.3 million in the same period last year.
• Research and development expenses increased to $9.6 million.

Risks

• Curis may experience delays or failures in its drug development programs.
• The company's drug candidates may not demonstrate sufficient safety and efficacy in clinical studies.
• Curis depends heavily on the success of emavusertib, and any delays could have a material adverse effect on its business.
• The company faces risks related to the transfer and encumbrance of royalty payments on Erivedge.
• Curis will require substantial additional capital to fund its business and may need to delay or reduce development if funding is not obtained.
• The company faces substantial competition and potential adverse decisions from regulatory authorities.
• Unstable market and economic conditions could disrupt operations and impact the ability to raise capital.

Future Outlook

Curis expects its existing cash, cash equivalents, and investments will enable its planned operations into 2025. The company plans to release and present updated clinical data from its ongoing studies throughout 2024.

Management Comments

• We are very pleased to have several opportunities to present additional patient data in R/R AML patients with a targeted mutation (mFLT3 or mSF), as well as progress updates for our R/R PCNSL and AML frontline triplet studies, at these prestigious oncology meetings, said James Dentzer, President and CEO of Curis.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on developing treatments for hematological malignancies. The presentation of clinical data at major oncology conferences is a key milestone for companies in this sector, and the financial results provide insight into the company's operational health and cash runway.

Comparison to Industry Standards

• Curis's Q1 2024 net loss of $11.9 million is within the range of losses reported by other clinical-stage biotech companies of similar size, such as Kura Oncology which reported a net loss of $38.8 million in Q1 2024, and Syndax Pharmaceuticals which reported a net loss of $40.8 million in Q1 2024.
• The revenue of $2.1 million, primarily from royalties, is typical for companies that have licensed out commercial rights to their products, such as Curis's Erivedge agreement with Genentech/Roche.
• The R&D expenses of $9.6 million are also in line with other companies in the clinical stage of drug development, where significant investment is required to advance clinical trials.
• The cash position of $40.7 million is a critical metric, and Curis's statement that it expects this to fund operations into 2025 is a positive sign for investors, although it is important to note that this is a relatively short runway compared to some other companies in the sector.
• Companies like Kura Oncology and Syndax Pharmaceuticals have cash positions of $380.9 million and $390.8 million respectively, which provides them with a longer runway.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for additional capital.
• Employees may be impacted by potential delays or reductions in development if funding is not secured.
• Patients may benefit from the continued development of emavusertib, but delays could impact the availability of new treatments.
• Creditors may be concerned about the company's financial stability and ability to repay debts.

Next Steps

• Curis will release topline clinical data from the TakeAim Leukemia study on May 14, 2024.
• The company will present updated clinical data at the ASCO and EHA conferences in late May and June 2024.
• Curis will continue to enroll patients in its TakeAim Lymphoma and TakeAim Leukemia studies.
• The company will initiate and enroll patients in its AML triplet study.
• Curis will provide updated clinical data from the TakeAim Leukemia study in mid-year 2024.
• Curis will provide updated clinical data from the TakeAim Lymphoma study in late 2024.
• Curis will provide initial safety data from the frontline triplet combination study of emavusertib with azacitidine and venetoclax in late 2024.

Key Dates

Keywords

emavusertib, IRAK4 inhibitor, AML, R/R AML, PCNSL, leukemia, lymphoma, clinical trials, biotechnology, financial results, ASCO, EHA, TakeAim Leukemia, TakeAim Lymphoma, mFLT3, mSF